umifenovir (arbidol) - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 0.72 [0.51, 1.01]> 10%2 studies (1 / 1)3.0 %criticalnot evaluable very lowcrucial-
clinical improvement (time to event analysis only) 0.75 [0.47, 1.20]> 10%1 study (- / 1)11.5 %criticalnot evaluable very lowcrucial-
clinical worsening 0.86 [0.06, 11.36]< 10%1 study (1 / -)54.6 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 0.97 [0.65, 1.46]> 10%2 studies (1 / 1)45.1 %criticalnot evaluable very lowimportant-
PCR-negative conversion (14-day) 2.80 [0.31, 25.53]> 10%1 study (1 / -)81.8 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.67 [0.10, 4.58]> 10%1 study (1 / -)34.1 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 0.94 [0.62, 1.42]> 10%1 study (- / 1)38.4 %criticalnot evaluable very lowimportant-
radiologic improvement (14-day) 0.18 [0.01, 3.99]> 10%1 study (1 / -)14.3 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.08 [0.00, 1.71]> 10%1 study (1 / -)5.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 87, 95